CDKN1C and cancer: Recent studies have reported that miR-221 and miR-222 regulate cell growth and cell cycle progression by targeting cyclin-dependent kinase inhibitor 1B (CDKN1B) and cyclin-dependent kinase inhibitor 1C (CDKN1C) in several cancer cell lines (26–30).